Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma
Authors
Keywords
-
Journal
ONCOGENE
Volume 41, Issue 27, Pages 3539-3553
Publisher
Springer Science and Business Media LLC
Online
2022-06-13
DOI
10.1038/s41388-022-02364-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Complex Interplay between Antioxidants and ROS in Cancer
- (2020) Isaac S. Harris et al. TRENDS IN CELL BIOLOGY
- Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer
- (2020) Léo Aubert et al. Nature Communications
- Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model
- (2020) Brittney S. Harrington et al. Cancers
- Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2
- (2020) Wenyang Li et al. GENES & DEVELOPMENT
- ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP
- (2020) Huijuan Fan et al. GENES & DEVELOPMENT
- The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol
- (2019) Gulsah Albayrak et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis
- (2019) Vinit Shanbhag et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sphingosine 1–phosphate signaling induces SNAI2 expression to promote cell invasion in breast cancer cells
- (2019) Wei Wang et al. FASEB JOURNAL
- YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells
- (2019) Shannon M. White et al. DEVELOPMENTAL CELL
- Mitochondrial metabolism promotes adaptation to proteotoxic stress
- (2019) Peter Tsvetkov et al. Nature Chemical Biology
- Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
- (2019) L Khoja et al. ANNALS OF ONCOLOGY
- Inhibition of Slug effectively targets leukemia stem cells via the Slc13a3/ROS signaling pathway
- (2019) Zhonghui Zhang et al. LEUKEMIA
- Uveal melanoma: Towards a molecular understanding
- (2019) Kyra N. Smit et al. PROGRESS IN RETINAL AND EYE RESEARCH
- How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma
- (2018) Theresa Steeb et al. EUROPEAN JOURNAL OF CANCER
- Targeting G protein-coupled receptor signalling by blocking G proteins
- (2018) Adrian P. Campbell et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting nucleotide exchange to inhibit constitutively active G protein α subunits in cancer cells
- (2018) Michael D. Onken et al. Science Signaling
- A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study
- (2018) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- A phase I study of elesclomol sodium in patients with acute myeloid leukemia
- (2016) David Hedley et al. LEUKEMIA & LYMPHOMA
- Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)
- (2015) Brian B. Hasinoff et al. BIOCHEMICAL PHARMACOLOGY
- The experimental power of FR900359 to study Gq-regulated biological processes
- (2015) Ramona Schrage et al. Nature Communications
- Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
- (2014) Fa-Xing Yu et al. CANCER CELL
- Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
- (2014) Xiaodong Feng et al. CANCER CELL
- Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target
- (2014) Nabil Amirouchene-Angelozzi et al. Molecular Oncology
- Copper is required for oncogenic BRAF signalling and tumorigenesis
- (2014) Donita C. Brady et al. NATURE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
- (2014) John D. Hayes et al. TRENDS IN BIOCHEMICAL SCIENCES
- Role of Nrf2 in Oxidative Stress and Toxicity
- (2013) Qiang Ma Annual Review of Pharmacology and Toxicology
- Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma
- (2013) Steven J. O'Day et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death
- (2013) G. Ambrosini et al. MOLECULAR CANCER THERAPEUTICS
- Inactivation of the HIF-1 /PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-Oxidants
- (2012) J. Kluza et al. CANCER RESEARCH
- The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
- (2012) Masazumi Nagai et al. FREE RADICAL BIOLOGY AND MEDICINE
- Copper Binding Agents Acting as Copper Ionophores Lead to Caspase Inhibition and Paraptotic Cell Death in Human Cancer Cells
- (2011) Saverio Tardito et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
- (2010) Helena Pópulo et al. MELANOMA RESEARCH
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells
- (2009) Ying Qu et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
- (2009) Steven O'Day et al. JOURNAL OF CLINICAL ONCOLOGY
- Ocular melanoma: relatively rare but requiring respect
- (2008) Carol L. Shields et al. CLINICS IN DERMATOLOGY
- Elesclomol induces cancer cell apoptosis through oxidative stress
- (2008) J. R. Kirshner et al. MOLECULAR CANCER THERAPEUTICS
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now